Figure 1 : Fenamate NSAIDs inhibit IL-1β processing and release.

From: Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models

Figure 1

(a) iBMDMs were primed with LPS (1 μg ml−1, 2 h) then pre-treated with NSAID at indicated concentration before stimulating with ATP (5 mM, 1 h). (bd) Murine primary BMDMs from WT (b) or NLRP3−/− (c,d) mice were primed with LPS (1 μg ml−1, 4 h) and pre-treated with NSAID (100 μM, 15 min) before stimulating with monosodium urate (MSU) crystals (250 μg ml−1, 4 h) (b), transfected ultrapure flagellin from Salmonella typhimurium (1 ng per 1,000 cells, 2 h) (c), or transfected DNA (0.66 ng per 1,000 cells, 4 h) (d). Supernatants were analysed by ELISA. Data are presented as mean % IL-1β release versus vehicle (DMSO) control+s.e.m (n=3 or 4). NS, not significantly different, *P<0.05, **P<0.01 determined by one-sample t-test versus hypothetical value of 100%.